Ulobetasol

Oct 15, 2019

Bausch Health's Ortho Dermatologics Business To Present Data At The Fall Clinical Dermatology Conference

Apr 30, 2019

FDA approves trade name Lexette(TM) (halobetasol propionate) foam, 0.05%

Feb 13, 2019

Mayne Pharma launches Lexette (TM) (halobetasol propionate) foam 0.05% in the United States

Oct 26, 2018

Mayne Pharma Acquires FDA-approved halobetasol foam, Complementing US Dermatology Portfolio

Oct 15, 2018

Bausch Health's Ortho Dermatologics Business To Present New Scientific Data During The Fall Clinical Dermatology Conference

Oct 02, 2018

Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On Bryhali(TM)* (Halobetasol Propionate) Lotion, 0.01% In The Journal Of Drugs In Dermatology

Aug 15, 2018

Ortho Dermatologics Resubmits U.S. New Drug Application For DUOBRII(TM) (halobetasol propionate and tazarotene) Lotion

Jun 18, 2018

FDA Issues Complete Response Letter For DUOBRII(TM) (Halobetasol Propionate and Tazarotene) Lotion

Apr 09, 2018

Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII(TM) In The Journal of the American Academy of Dermatology

Sep 05, 2017

Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118